| Trial ID: | L0722 |
| Source ID: | IRCT20081110001444N6
|
| Associated Drug: |
Silymarin
|
| Title: |
The Efficacy of Silymarin and Vitamin E in the Treatment of the Non-Alcoholic Fatty Liver Disease: A Clinical Trial
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-Alcoholic Fatty Liver Disease. <br>Nonalcoholic steatohepatitis (NASH);K75.81
|
| Interventions: |
Intervention 1: Intervention group 1 silymarin: Silymarin 140 mg BID (with the brand name of Livergol from Goldaru Pharmaceutical Company, Iran) for four months.Additionally, they were all given consultation for standard weight-loss programs and persuaded
|
| Outcome Measures: |
ALanin aminotransferas measurements. Timepoint: They were received at the baseline and then after four months for ALT measurements. Method of measurement: autoanlizer.;Ultrasonographic evaluations of their liver. Timepoint: first and four months later. Method of measurement: General Electric ultrasound device,.nan
|
| Sponsor/Collaborators: |
Shahid Sadoughi University of Medical Sciences-Yazd, Iran
|
| Gender: |
All
|
| Age: |
20 years60 years
|
| Phases: |
Phase 3
|
| Enrollment: |
80
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The patients were received so as to take daily doses of vitamins E (400 IU) and Silymarin 140 mg BID (with the bra
|
| Start Date: |
02/11/2019
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
5 November 2019
|
| Locations: |
Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/41620
|
